Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology companies Abmaxis and MaimoniDex RA are to jointly develop a therapeutic human monoclonal antibody for the treatment of rheumatoid arthritis and other inflammatory diseases.
Subscribe to our email newsletter
Based on its discovery of a disease-causing molecule found only in the joints of RA patients, MaimoniDex has developed a murine monoclonal antibody that has shown bioactivities both in vitro and in vivo. Using its unique antibody engineering technology, Abmaxis will humanize and optimize the murine antibody to develop a drug candidate suitable for potential therapeutic use.
Under the terms of the agreement, MaimoniDex will pay Abmaxis an upfront technology license fee and Abmaxis is also entitled to receive future milestone payments and royalties on product sales.
“Working with Abmaxis, a specialist in antibody humanization and optimization with an excellent track record of successful partnerships, will enable the production of a commercially viable humanized monoclonal antibody for treating rheumatoid arthritis,” commented Dr Itshak Golan, president and CEO of MaimoniDex.